Neurone Specific Enolase as a Tumour Marker in Small Cell Lung Cancer
Author Information
Author(s): M. Harding, J. McAllister, G. Hulks, D. Vernon, R. Monie, J. Paul, S.B. Kaye
Primary Institution: University of Glasgow
Hypothesis
Can neurone specific enolase (NSE) serve as a prognostic marker in small cell lung cancer (SCLC)?
Conclusion
Higher pretreatment NSE levels are associated with poorer survival outcomes in patients with limited stage small cell lung cancer.
Supporting Evidence
- Median NSE levels were significantly higher in patients with extensive disease compared to those with limited disease.
- 76% of patients receiving chemotherapy responded to treatment, with normalisation of NSE levels in most cases.
- An increase of 5 ng ml-1 in NSE was associated with a 10% reduction in median survival.
Takeaway
Doctors measured a substance called NSE in the blood of lung cancer patients to see if it could help predict how long they might live. They found that higher levels of NSE meant a shorter life expectancy.
Methodology
Serum NSE levels were measured in patients with small cell lung cancer, and their relationship with survival was analyzed using statistical models.
Potential Biases
Potential bias due to the exclusion of patients with extensive disease who may have received suboptimal treatment.
Limitations
The study had a small sample size and focused only on patients with limited stage SCLC.
Participant Demographics
Patients diagnosed with small cell lung cancer, with a mix of limited and extensive disease stages.
Statistical Information
P-Value
0.004
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website